Another ADC Buyout - Just not SPL, page-21

I would like to think that was the case but let's not forget that after the anniversary of our second ADC agreement signed with Merck, Merck signed an agreement with Daiichi in October 2023 committing up to $22 billion with $.5 billion being paid upfront for their ADCs


...... so whether Merck are still interested remains to be seen ? Maybe Cheryl will get a deal inked because we know the previous CEO couldn't in her 17+ year tenure even after touting on multiple occasions over the years that they were in commercial in confidence discussions with several potential partners ? Remember this little gem of a comment in the 25th Nov 2021 ASX announcement right before the AGM.... 2 years plus of discussions with several potential partners that appears to have gone nowhere at this stage ?






https://www.reuters.com/business/he...llaboration-sankyos-antibody-drug-2023-10-19/

Merck signs $5.5 billion deal with Daiichi for cancer therapy development

• Deal will see Merck pay $5.5 bln, and potentially up to $22 bln
• ADC drugs designed to target cancer
• Japanese firm has six ADC candidates in pipeline
• Daiichi Sankyo shares surge 12% in early trading